Andrea Lee, MD
Neurology · Kansas City, KSNPI 1023452653
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Amneal Pharmaceuticals LLC accounts for 63.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $2,079 and has fallen 97.0% since, to $62 in 2025.
Across 42 payments — averaging $67.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$2K
- Medtronic$412
- AbbVie$146
- Hospira, Inc.$123
- Teva Pharmaceuticals USA, Inc.$79
- UCB, Inc.$69
- plus $205 from 7 others
What the payments were for
- Speaking & faculty fees$1,50053%
- Travel & lodging$221%
- Food & beverage$1,23944%
- Education$672%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 7 | $1,792 |
| Medtronic(2 entities) | 7 | $412 |
| AbbVie | 3 | $146 |
| Hospira, Inc. | 8 | $123 |
| Teva Pharmaceuticals USA, Inc. | 2 | $79 |
| UCB, Inc. | 4 | $69 |
| Acadia Pharmaceuticals Inc | 4 | $58 |
| Kyowa Kirin, Inc. | 1 | $41 |
| Merz Pharmaceuticals, LLC | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Argenx US, Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,827 in reported general payments places this provider in the 65th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 73 | $406,397 |
| IngrezzaValbenazine Tosylate | 42 | $338,100 |
| RytaryCarbidopa/Levodopa | 207 | $325,458 |
| AustedoDeutetrabenazine | 21 | $144,407 |
| GocovriAmantadine Hcl | 23 | $113,006 |
| InbrijaLevodopa | 51 | $93,562 |
| NeuproRotigotine | 65 | $75,726 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,148 | $47,408 |
| RestasisCyclosporine | 41 | $29,725 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 424 | $18,392 |
| Primidone | 361 | $10,693 |
| Rivastigmine | 33 | $9,932 |
| CrexontCarbidopa/Levodopa | 14 | $9,313 |
| Rasagiline Mesylate | 47 | $7,363 |
| Entacapone | 32 | $6,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $58 | $406,39773 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $12 | $338,10042 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $1,792 | $334,770221 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $79 | $144,40721 claims |
| Acorda Therapeutics, IncInbrija | $20 | $93,56251 claims |
| UCB, Inc.Neupro | $69 | $75,72665 claims |
| AbbVieRestasis | $146 | $29,72541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 131 neurology providers in Kansas.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Rajesh PahwaKansas City$889K
- Richard DubinskyKansas City$122K
- Jeffrey BurnsKansas City$115K
- Amanda ThuringerKansas City$87K
- Mamatha PasnoorKansas City$86K
- Michael AbrahamKansas City$48K
- Constantine FarmakidisKansas City$25K
- Andrew CreedKansas City$16K
- James AppelbaumKansas City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.